Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.50 |
| ▸ | ABAT | P80404 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074403 | 1.00 | CYP2A6 (0.50) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL7542217 | 0.90 | ALDH1A1 (0.59) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL2301281 | 0.90 | ALDH1A1 (0.59) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL18821769 | 0.88 | MAPT (0.64) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL28987870 | 0.88 | PTGS1 (0.44) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL15132500 | 0.88 | CYP2A6 (0.73) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL26351687 | 0.88 | CYP2A6 (0.73) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL13858891 | 0.88 | MAPT (0.64) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL15132514 | 0.88 | ALDH5A1 (0.73) | ALDH5A1ABATALDH1A1KDM4ERAB9A | |
| SCHEMBL27902262 | 0.88 | ALDH5A1 (0.73) | ALDH5A1ABATALDH1A1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890351-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2018-02-13 | — | — | US | claimed |
| EP-2741731-B1 | ENCAPSULATES | PROCTER & GAMBLE (US) | 2017-05-17 | — | — | EP | claimed |
| EP-2741731-A1 | ENCAPSULATES | The Procter and Gamble Company (US) | 2014-06-18 | — | — | EP | claimed |
| US-20130039962-A1 | ENCAPSULATES | ENCAPSYS, LLC | 2013-02-14 | — | — | US | claimed |
| WO-2013022949-A1 | ENCAPSULATES | THE PROCTER & GAMBLE COMPANY (US) | 2013-02-14 | — | — | WO | claimed |
| US-20070043003-A1 | Novel compounds for the prophylaxis and treatment of inflammatory bowel diseases | HIKMA PHARMACEUTICALS CO., LTD. (JO) | 2007-02-22 | — | — | US | claimed |
| EP-1688413-A1 | Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases | Hikma Pharmaceuticals Co. Ltd. (JO) | 2006-08-09 | — | — | EP | claimed |
| CN-112604675-B | Preparation method and application of azobenzene dicarboxamide bridged beta-cyclodextrin chiral stationary phase | 南昌大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-113817152-A | Flame-retardant anti-dripping copolyester based on high-temperature self-crosslinking and preparation method and application thereof | 四川大学 | 2021-12-21 | — | — | CN | disclosed |
| CN-112604675-A | Preparation method and application of azobenzene dicarboxamide bridged beta-cyclodextrin chiral stationary phase | 南昌大学 | 2021-04-06 | — | — | CN | disclosed |
| US-9890351-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890351-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890351-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2018-02-13 | — | — | US | disclosed |
| EP-0188675-B1 | ULTRATHIN POLYMERIC IMINE FILMS AND PROCESS FOR MAKING THE SAME | Research Development Corporation of Japan (JP) | 1991-06-05 | — | — | EP | disclosed |
| US-4966743-A | Process for making ultrathin polymeric imine films | RESEARCH DEVELOPMENT CORPORATION OF JAPAN (JP) | 1990-10-30 | — | — | US | disclosed |
| US-4818593-A | Ultrathin heteroaromatic polymer films and process for making the same | RESEARCH DEVELOPMENT CORP. OF JAPAN (JP) | 1989-04-04 | — | — | US | disclosed |
| US-4778720-A | PRODUCT OF DIAMINE AND DIIMINE SCHIFF BASE; SEMICONDUCTORS | RESEARCH DEV. CORP. OF JAPAN (JP) | 1988-10-18 | — | — | US | disclosed |
| US-4681799-A | Ultrathin polymeric imine films and process for making the same | RESEARCH DEVELOPMENT CORP. OF JAPAN (JP) | 1987-07-21 | — | — | US | disclosed |
| EP-0188675-A1 | Ultrathin polymeric imine films and process for making the same | Research Development Corporation of Japan (JP) | 1986-07-30 | — | — | EP | disclosed |
| US-3948861-A | Polyamide-imides from bis-imide and dialdoxime | RHONE-POULENC S.A. (FR) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039962-A1 | ENCAPSULATES | ABCB4, PPIB, FLNB | CYP2A6 2489/4885HSD17B10 876/4885ALDH5A1 302/4885 |
| US-20070043003-A1 | Novel compounds for the prophylaxis and treatment of inflammatory bowel diseases | SI, ALPI, VIP | CYP2A6 983/4885HSD17B10 1964/4885ALDH5A1 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.